Journal of AIDS & Clinical Research

Bogner JR

Publications

• Research Article
  Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid with FTC/TDF in Treatment-Naïve HIV-1 Patients
  Author(s): Brinson C, Bogner JR, Nelson M, Podzamczer D, Quinson AM, Drulak M, Andrade-Villanueva J, Cahn P, Santiago S and Gathe JBrinson C, Bogner JR, Nelson M, Podzamczer D, Quinson AM, Drulak M, Andrade-Villanueva J, Cahn P, Santiago S and Gathe J
  
  Background: We report 96- and 144-week follow-up data from VERxVE, demonstrating that nevirapine (NVP) extended release (XR) 400 mg once daily was non-inferior to NVP immediate release (IR) 200 mg twice daily, each administered on a backbone of emtricitabine/tenofovir. Methods: VERxVE was a double-blind, double-dummy, non-inferiority study in adults with screening viral load (VL) >1000 copies/mL and CD4+ cell count <400 cells/mm3 (males) or <250 cells/mm3 (females). Randomisation was stratified by baseline VL (copies/mL) ≤ 100,000 or >100,000. The primary endpoint was confirmed virologic response (<50 copies/mL) at week 48. Cochran’s statistic incorporating baseline VL strata tested non-inferiority of XR efficacy versus IR. Secondary endpoints included 144-week sustained virologic response and safety. Results: In all, 1011 patients were randomised and treated w.. Read More»
  DOI: 10.4172/2155-6113.1000233

  Abstract PDF